Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Cancer. 2019 Apr 5;125(14):2400–2408. doi: 10.1002/cncr.32061

Figure 3: Overall survival.

Figure 3:

Data are from the all-treated set (all randomized patients who received study drug). Kaplan Meier curves depicting overall survival for patients treated with axitinib + dalantercept (blue line) vs. axitinib + placebo (red line). Median follow-up on both arms was 17.8 months at time of analysis. CI=confidence interval. HR=hazard ratio. NE=not estimable. OS=overall survival.